CHM 0.00% 1.8¢ chimeric therapeutics limited

the neurosurgeons need to be qualified to administer car t cell...

  1. 23 Posts.
    lightbulb Created with Sketch. 14
    the neurosurgeons need to be qualified to administer car t cell therapies (in our case dual intraventicular administration). Now given that car T cells have historically only been used for treating blood cancers, then it follows that neurosurgeons would not be experts in car T.

    importantly, there are a number of existing oncology therapies that involve intraventricular administration into the brain (to overcome the blood brain barrier).

    furthermore, given a successful car t treatment for glioblastoma would cost patients up to USD1m I don’t see why big pharma couldn’t train the relevant specialist. I mean the throw money at them for conferences etc
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.8¢
Change
0.000(0.00%)
Mkt cap ! $15.52M
Open High Low Value Volume
1.9¢ 1.9¢ 1.8¢ $20.37K 1.114M

Buyers (Bids)

No. Vol. Price($)
6 335137 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 189531 4
View Market Depth
Last trade - 16.10pm 19/06/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.